Teva Pharmaceutical Industries (NYSE:TEVA) was upgraded by equities research analysts at ValuEngine from a “buy” rating to a “strong-buy” rating in a research note issued to investors on Friday, ValuEngine reports.
Several other research analysts also recently commented on the company. Guggenheim began coverage on Teva Pharmaceutical Industries in a research note on Thursday, September 12th. They issued a “neutral” rating for the company. Wolfe Research began coverage on Teva Pharmaceutical Industries in a research note on Friday, July 19th. They issued a “peer perform” rating and a $9.00 target price for the company. Morgan Stanley downgraded Teva Pharmaceutical Industries from an “equal weight” rating to an “underweight” rating and cut their target price for the stock from $16.00 to $6.00 in a research note on Monday, July 15th. Wells Fargo & Co cut their target price on Teva Pharmaceutical Industries from $17.00 to $8.00 and set a “market perform” rating for the company in a research note on Monday, September 30th. Finally, Raymond James cut their target price on Teva Pharmaceutical Industries from $22.00 to $15.00 and set an “outperform” rating for the company in a research note on Thursday, August 8th. Six research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, six have given a buy rating and one has given a strong buy rating to the company. The stock presently has a consensus rating of “Hold” and an average target price of $10.78.
Shares of TEVA stock traded up $0.83 on Friday, hitting $9.30. 34,192,717 shares of the stock were exchanged, compared to its average volume of 16,922,125. The company has a current ratio of 0.96, a quick ratio of 0.62 and a debt-to-equity ratio of 1.73. The firm has a market capitalization of $9.32 billion, a PE ratio of 3.32, a P/E/G ratio of 0.89 and a beta of 1.73. Teva Pharmaceutical Industries has a one year low of $6.07 and a one year high of $23.97. The firm’s 50 day moving average is $7.51 and its two-hundred day moving average is $8.90.
Several large investors have recently added to or reduced their stakes in TEVA. AdvisorNet Financial Inc raised its holdings in shares of Teva Pharmaceutical Industries by 71.3% in the 3rd quarter. AdvisorNet Financial Inc now owns 3,665 shares of the company’s stock valued at $25,000 after acquiring an additional 1,525 shares in the last quarter. First Interstate Bank purchased a new stake in shares of Teva Pharmaceutical Industries in the 2nd quarter valued at about $28,000. Motco purchased a new position in shares of Teva Pharmaceutical Industries during the 3rd quarter valued at about $28,000. Lindbrook Capital LLC raised its holdings in shares of Teva Pharmaceutical Industries by 76.6% during the 3rd quarter. Lindbrook Capital LLC now owns 4,461 shares of the company’s stock valued at $31,000 after buying an additional 1,935 shares in the last quarter. Finally, Pacer Advisors Inc. purchased a new position in shares of Teva Pharmaceutical Industries during the 2nd quarter valued at about $32,000. 58.21% of the stock is currently owned by hedge funds and other institutional investors.
About Teva Pharmaceutical Industries
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.
Featured Story: What is the S&P 500 Index?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.